Telix Pharmaceuticals (TLX) Expected to Announce Quarterly Earnings on Thursday

Telix Pharmaceuticals (NASDAQ:TLX) is expected to be announcing its H2 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of $0.0493 per share and revenue of $421.5040 million for the quarter. Investors can find conference call details on the company’s upcoming H2 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 5:30 PM ET.

Telix Pharmaceuticals Stock Performance

NASDAQ TLX opened at $6.93 on Thursday. The company’s fifty day moving average is $7.92 and its two-hundred day moving average is $9.57. Telix Pharmaceuticals has a 52-week low of $6.82 and a 52-week high of $30.36.

Institutional Trading of Telix Pharmaceuticals

Several large investors have recently added to or reduced their stakes in TLX. Millennium Management LLC bought a new position in shares of Telix Pharmaceuticals in the third quarter valued at approximately $1,883,000. Lazard Asset Management LLC bought a new position in Telix Pharmaceuticals in the 3rd quarter valued at $1,097,000. Russell Investments Group Ltd. acquired a new position in Telix Pharmaceuticals in the second quarter worth $975,000. Private Advisor Group LLC boosted its stake in Telix Pharmaceuticals by 67.3% in the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock worth $403,000 after purchasing an additional 16,945 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Telix Pharmaceuticals during the second quarter worth $564,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on TLX shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday, January 27th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.